China-based Hebei Viroad Biotechnology has invested €5m ($7m) in Gilupi, a Germany-based drugs developer, as part of a wider licensing agreement”for large parts of Asia”.
Gilupi raised €3.6m in its series C round in January 2011.
Previous investors include state- and corporate-backed early-stage investment manager High-Tech Gründerfonds (HTGF) and regional banks and state funds Aurelia Technologie-Fonds I, KfW and BC Brandenburg Capital and sparkassen of the state of Brandenburg (S-UBG).
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
